注射用哌拉西林/舒巴坦治疗泌尿系统感染的疗效评价  

Evaluation of the Effect of Piperacillin/Sulbactam in the Treatment of Acute Urinary System Tract Infection

作　　者：曾跃红[1] 田海清[1] 郭利民[1] 李伟[1] 

机构地区：[1]益阳市中心医院,湖南益阳413000

出　　处：《药物流行病学杂志》2013年第5期225-227,共3页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:比较哌拉西林/舒巴坦与美洛西林/舒巴坦治疗急性细菌性中重度泌尿系统感染的临床疗效,评价其有效性和安全性。方法:76例急性细菌性中重度泌尿系统感染患者随机分为试验组和对照组各38例,分别给予哌拉西林/舒巴坦2.5 g或美洛西林/舒巴坦2.5 g,溶于0.9%氯化钠注射液250 ml,ivd,q8h或q12h,1个疗程为7 d。连续治疗2个疗程后对两组临床疗效、细菌学疗效、药品不良反应等进行综合评价。结果:试验组和对照组痊愈率分别为57.9%和47.4%,总有效率分别为84.2%和78.9%。两组细菌清除率分别为89.2%和82.5%,治疗后细菌转阴率分别为89.5%和86.9%;不良反应发生率均为2.63%。两组各项评价指标比较,差异均无统计学意义(P>0.05)。结论:哌拉西林/舒巴坦对于治疗急性细菌性中重度泌尿系统感染安全有效。Objective：To evaluate of the clinical effect and safety of PIP/SBT and MEZ/SBT in the treatment of moderate and severe acute bacterial infection of the urinary system tract.Methods：76 urinary tract infection patients were randomly divided into trial drug group（PIP/SBT） and controlled drug group（MEZ/SBT） with 38 cases each,7 days for a course of treatment.After 2 courses of treatment,their clinical bacteriological efficacy and adverse events were evaluated. Results：The cure rates of the trial drug group and controlled drug group were 57.9%and 47.4%,and the total effective rates were 84.2%and 78.9%.Their bacterial clearance rates were 89.2%and 82.5%,the negative rates of bacteria after treatment were 89.5%and 86.9%,and the adverse effects rate of the two groups was 2.63%.There was no significant difference in each evaluation index（P 0.05）.Conclusion：PIP/SBT had their good clinical effect and safety in the treatment of the moderate and severe acute bacterial urinary system tract infection.

关 键 词：哌拉西林 舒巴坦 美洛西林 舒巴坦 泌尿系统感染 疗效评价 

分 类 号：R978.11[医药卫生—药品]